Assesses CRVO and BRVO visual prognosis using BCVA, macular edema on OCT, and ischemia index (nonperfusion on FA/OCTA), with anti-VEGF treatment loading dose criteria.
BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).
BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.
Assesses CRVO and BRVO visual prognosis using BCVA, macular edema on OCT, and ischemia index (nonperfusion on FA/OCTA), with anti-VEGF treatment loading dose criteria
Each component has a specific meaning:
Note: Interpret the rvo treatment result against the clinical thresholds and context described above.
Enter the BCVA, macular edema on OCT, ischemia index for the patient or scenario you are assessing. Assesses CRVO and BRVO visual prognosis using BCVA, macular edema on OCT, and ischemia index (nonperfusion on FA/OCTA), with anti-VEGF treatment loading dose criteria. Use the rvo treatment result to inform your clinical assessment.